- Home
- NMS vs CUE Comparison
NMS vs CUE Comparison
Compare NMS & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMS
- CUE
- Stock Information
- Founded
- NMS 1993
- CUE 2014
- Country
- NMS United States
- CUE United States
- Employees
- NMS N/A
- CUE N/A
- Industry
- NMS Finance Companies
- CUE Biotechnology: Pharmaceutical Preparations
- Sector
- NMS Finance
- CUE Health Care
- Exchange
- NMS Nasdaq
- CUE Nasdaq
- Market Cap
- NMS 68.7M
- CUE 58.9M
- IPO Year
- NMS N/A
- CUE 2018
- Fundamental
- Price
- NMS $11.36
- CUE $0.63
- Analyst Decision
- NMS
- CUE Strong Buy
- Analyst Count
- NMS 0
- CUE 3
- Target Price
- NMS N/A
- CUE $3.00
- AVG Volume (30 Days)
- NMS 12.0K
- CUE 163.7K
- Earning Date
- NMS 01-01-0001
- CUE 05-12-2025
- Dividend Yield
- NMS 4.11%
- CUE N/A
- EPS Growth
- NMS N/A
- CUE N/A
- EPS
- NMS N/A
- CUE N/A
- Revenue
- NMS N/A
- CUE $7,991,000.00
- Revenue This Year
- NMS N/A
- CUE N/A
- Revenue Next Year
- NMS N/A
- CUE $25.99
- P/E Ratio
- NMS N/A
- CUE N/A
- Revenue Growth
- NMS N/A
- CUE 13.83
- 52 Week Low
- NMS $9.21
- CUE $0.45
- 52 Week High
- NMS $12.18
- CUE $1.99
- Technical
- Relative Strength Index (RSI)
- NMS 32.80
- CUE 37.72
- Support Level
- NMS $11.35
- CUE $0.61
- Resistance Level
- NMS $11.59
- CUE $0.71
- Average True Range (ATR)
- NMS 0.09
- CUE 0.06
- MACD
- NMS -0.02
- CUE -0.00
- Stochastic Oscillator
- NMS 13.51
- CUE 17.84
About NMS Nuveen Minnesota Quality Municipal Income Fund
Nuveen Minnesota Quality Municipal Income Fund is a diversified closed-end management investment company. The Fund's primary investment objective is current income exempt from both regular federal income taxes and Minnesota state income taxes and its secondary investment objective is the enhancement of portfolio value.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.